1.Prevention of respiratory syncytial viral infections in late preterm infants.
Koravangattu SANKARAN ; Mila KALAPPURACKAL ; Ben TAN
Chinese Journal of Contemporary Pediatrics 2013;15(4):241-248
RSV prophylaxis is not routine in infant born 33 to 35 weeks gestation. Risk scoring tool can be utilized to identify infants that have significant chance for hospitalization. Premature birth is a leading cause of infant mortality and chronic pulmonary morbidity, therefore prevention of RSV hospitalization though immune prophylaxis in late preterm infants appears attractive.
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Hospitalization
;
Humans
;
Infant, Newborn
;
Infant, Premature
;
Intensive Care Units, Neonatal
;
Palivizumab
;
Respiratory Syncytial Virus Infections
;
prevention & control
2.Children hospitalized with respiratory syncytial virus infection in Saskatchewan pediatric tertiary care centers, 2002-2005.
Ayisha KURJI ; Ben TAN ; Jaya BODANI ; Bonnie JANZEN ; Athena MCCONNELL ; Rachana BODANI ; Derek RAJAKUMAR ; Anil SHARMA ; Koravangattu SANKARAN
Chinese Journal of Contemporary Pediatrics 2014;16(10):1005-1013
OBJECTIVETo describe the epidemiology and severity of illness of children hospitalized with respiratory syncytial virus (RSV) infection, including those who received palivizumab prophylaxis, at Royal University Hospital (RUH), Saskatoon and Regina General Hospital (RGH) from July 2002 to June 2005.
METHODSChildren hospitalized for ≥ 24 hours with laboratory-confirmed RSV infection were enrolled, and their health records were retrospectively reviewed for patient demographics and referral patterns, use of palivizumab prophylaxis, severity of infection (length of hospitalization, need for and duration of pediatric intensive care and mechanical ventilation) and outcome of infection.
RESULTSA total of 590 children (324 males) were hospitalized over the three years. The median chronological age at admission was 5.3 months, and median hospital stay was 4.0 days. Gestational age at birth was ≥ 36 weeks in 82.4% of patients. RSV disease severity was mild to moderate in 478 patients (81.0%) and severe in 110 (18.6%). Thirty-nine patients (6.6%) required pediatric intensive care unit admission, for a median of 5.0 days. Twenty-two of these patients (56%) were mechanically ventilated for a median of 6.0 days. Two children died, not attributed to RSV infection. Twenty-two patients had received palivizumab prophylaxis before hospital admission, with 18 completing at least 2 of the monthly doses. Most of these children (17/22) had mild to moderate illness.
CONCLUSIONSRSV causes significant morbidity in Saskatchewan, affecting predominantly term infants. The majority of illness is mild to moderate. Some patients who have received palivizumab may still develop significant RSV disease.
Adolescent ; Antibodies, Monoclonal, Humanized ; therapeutic use ; Child ; Child, Preschool ; Female ; Hospitalization ; Humans ; Infant ; Infant, Newborn ; Male ; Palivizumab ; Respiratory Syncytial Virus Infections ; epidemiology ; prevention & control ; Saskatchewan ; epidemiology ; Tertiary Care Centers ; Time Factors
3.Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia.
Young Mi HAN ; Hyun Joo SEO ; Seo Heui CHOI ; Yu Jin JUNG ; So Yoon AHN ; Hye Soo YOO ; Se In SUNG ; Jae Won SHIM ; Yeon Kyung LEE ; Sun Young KO ; Son Moon SHIN ; Jong Hee HWANG ; Jang Hoon LEE ; Byung Min CHOI ; Eun Sun KIM ; Ji Hyun JEON ; Sung Shin KIM ; Yun Sil CHANG ; Won Soon PARK
Journal of Korean Medical Science 2015;30(7):924-931
The aim of this study was to observe the effects of prophylactic palivizumab on hospitalization secondary to respiratory syncytial virus (RSV) infection (RSVhospitalization) in former very low birth weight infants (VLBWI) with bronchopulmonary dysplasia (BPD). This study also sought to identify the risk factors of RSVhospitalizationin this particular infant population. A prospective observational study was conducted between September 2007 and April 2008 in seven Korean hospitals. Children with a history of very low birth weight, a diagnosis of BPD and who were <2 yr old at the onset of the RSV season were included in this study. Palivizumab injections were administered monthly for a maximum of five months during the RSV season. RSVhospitalization rates were reviewed, and RSVhospitalization rates between subgroups were categorized by gestational age, birth weight, and duration of ventilator care. A total of 90 subjects completed the follow-up interviews. The mean gestational age at birth was 26.1+/-1.7 weeks, and the mean birth weight was 889.4+/-222.2 g. The incidence of RSVhospitalization in the study population was 8.9% (8/90), and the mean hospital stay was 11.0+/-5.5 days, including one death. There were no statistically significant differences in the patients' demographic characteristics or risk factors for RSV hospitalization. When subgroup analyses were conducted, there were still no statistically significant differences. The administration of palivizumab prophylaxis during the entire RSV season is important in VLBWI with BPD, regardless of their gestational age and birth weight, or previous ventilator dependency.
Antibiotic Prophylaxis/*methods
;
Antiviral Agents/*therapeutic use
;
Birth Weight
;
Bronchopulmonary Dysplasia/*complications
;
Female
;
Gestational Age
;
Hospitalization/statistics & numerical data
;
Humans
;
Infant
;
Infant, Newborn
;
Infant, Premature
;
*Infant, Very Low Birth Weight
;
Length of Stay
;
Male
;
Palivizumab/*therapeutic use
;
Prospective Studies
;
Respiratory Syncytial Virus Infections/drug therapy/*epidemiology/prevention & control
;
Respiratory Syncytial Viruses/drug effects
;
Risk
;
Risk Factors
4.Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea.
Jang Hoon LEE ; Chun Soo KIM ; Yun Sil CHANG ; Jung Hwan CHOI
Journal of Korean Medical Science 2015;30(Suppl 1):S104-S110
This study was done to evaluate respiratory syncytial virus (RSV) related readmission (RRR) and risk factors of RRR in preterm infants < 34 weeks gestational age (GA) within 1 yr following discharge from the neonatal intensive care unit (NICU). Infants (n = 1,140) who were born and admitted to the NICUs of 46 hospitals in Korea from April to September 2012, and followed up for > 1 yr after discharge from the NICU, were enrolled. The average GA and birth weight of the infants was 30(+5) +/- 2(+5) weeks and 1,502 +/- 474 g, respectively. The RRR rate of enrolled infants was 8.4% (96/1,140), and RSV accounted for 58.2% of respiratory readmissions of infants who had laboratory tests confirming etiological viruses. Living with elder siblings (odd ratio [OR], 2.68; 95% confidence interval [CI], 1.68-4.28; P < 0.001), and bronchopulmonary dysplasia (BPD) (OR, 2.95; 95% CI, 1.44-6.04; P = 0.003, BPD vs. none) increased the risk of RRR. Palivizumab prophylaxis (OR, 0.06; 95% CI, 0.03-0.13; P < 0.001) decreased the risk of RRR. The risk of RRR of infants of 32-33 weeks' gestation was lower than that of infants < 26 weeks' gestation (OR, 0.11; 95% CI, 0.02-0.53; P = 0.006). This was a nationwide study that evaluated the rate and associated risk factors of RRR in Korean preterm infants. Preterm infants with BPD or living with siblings should be supervised, and administration of palivizumab to prevent RRR should be considered.
Antiviral Agents/therapeutic use
;
Birth Weight
;
Bronchopulmonary Dysplasia/drug therapy/pathology
;
Female
;
Gestational Age
;
Humans
;
Infant
;
Infant, Newborn
;
Infant, Premature
;
Intensive Care Units, Neonatal
;
Male
;
Odds Ratio
;
Palivizumab/therapeutic use
;
Patient Discharge
;
Patient Readmission
;
Republic of Korea
;
Respiratory Syncytial Virus Infections/drug therapy/*pathology/virology
;
Respiratory Syncytial Viruses/*isolation & purification
;
Risk Factors
;
Siblings